Jiangsu Hengrui Medicine Co., Ltd. Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

600276

Rank in Stocks #544
Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged... Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged in the full spectrum of pharmaceutical operations, from the initial discovery and development of medications to their manufacturing and worldwide distribution. The company is actively advancing a substantial pipeline of drug candidates, which includes Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403. These prospective treatments are aimed at a diverse range of medical conditions, primarily focusing on oncology, metabolic disorders, pain management, and autoimmune diseases, among others. The enterprise was founded in 1970 and maintains its corporate headquarters in Lianyungang, China.
Share Price
$6.89
Market Cap
$43.94B
Change (1 day)
-2.91%
Change (1 year)
-24.78%
Country
CN
Trade Jiangsu Hengrui Medicine Co., Ltd. (600276)

Category

Healthcare
P/B ratio for Jiangsu Hengrui Medicine Co., Ltd. (600276)
P/B ratio as of October 2026 TTM: 4.71
According to Jiangsu Hengrui Medicine Co., Ltd. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 4.71. At the end of 2024 the company had a P/B ratio of 6.39.
P/B ratio history for Jiangsu Hengrui Medicine Co., Ltd. from 2001 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
2026 (TTM) 4.71 -25.48%
2025 6.32 -1.09%
2024 6.39 -9.65%
2023 7.07 9.04%
2022 6.49 -29.84%
2021 9.24 -52.24%
2020 19.35 24.50%
2019 15.55 57.24%
2018 9.89 -5.23%
2017 10.43 45.32%
2016 7.18 -10.85%
2015 8.05 63.76%
2014 4.92 -13.09%
2013 5.66 13.80%
2012 4.97 -8.81%
2011 5.45 -40.25%
2010 9.12 4.84%
2009 8.70 25.59%
2008 6.93 -35.14%
2007 10.68 89.97%
2006 5.62 451.70%
2005 1.02 5.76%
2004 0.96 -9.87%
2003 1.07 -10.67%
2002 1.20 -6.19%
2001 1.28 0.00%
P/B ratio for similar companies or competitors